Skip to content
value.today

Dare Bioscience, Inc.

🇺🇸 San Diego, California, USABiotechnologyFounded 2005
Total raised
$61 M
6 rounds on record
Latest round
$13 M
Nov 2012
First round on record
Jul 2009
Today
Went public
See the company page

Dare Bioscience, Inc. is listed today as Daré Bioscience, Inc.: market value, financials and filings are on its company page.

Funding rounds

6 counted as startup funding, 4 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Dare Bioscience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$12 MPrivate placement after listing$10 to $50 million

Dare Bioscience, Inc.: Private sale, Aug 2026

Investors in this round

12 investors had bought by the notice of Aug 20, 2026: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Dare Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • MarDee Martucci Haring-Layton · Executive Officer · Chief Accounting Officer
  • Sabrina Martucci Johnson · Executive Officer, Director · President and Chief Executive Officer
  • Gregory W. Matz · Director
  • Jessica D. Grossman · Director
  • Robin J. Steele · Director
  • Susan L. Kelley · Director
  • William H. Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ladenburg Thalmann & Co. Inc. (CRD 000000505) · broker-dealer Ladenburg Thalmann & Co. Inc. (CRD 000000505) · New York, New YorkSold in all US states

Remarks in the notice

  • On the amounts: “The total offering amount reflects proceeds if all warrants, consisting of 8,759,162 and 175,183 shares of common stock exercisable at $1.37 and $2.1235 per share, respectively, are exercised for cash. No warrants have been exercised as of this filing.”

Signed by MarDee Haring-Layton, Chief Accounting Officer. Source: SEC Form D, newest notice filed Aug 20, 2026. Read the notice at the SEC.

optionsSEC
Dec 2023$2 MPrivate placement after listingUnder $2 million

Dare Bioscience, Inc.: Private sale, Dec 2023

Investors in this round

1 investor had bought by the notice of Dec 26, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Dare Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $4 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lisa Martucci Walters-Hoffert · Executive Officer
  • Sabrina Martucci Johnson · Executive Officer, Director
  • Cheryl R. Blanchard · Director
  • Gregory W. Matz · Director
  • Jessica D. Grossman · Director
  • Robin J. Steele · Director
  • Sophia N. Ononye-Onyia · Director
  • Susan L. Kelley · Director
  • William H. Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total offering amount includes the $0.3467 per underlying share of common stock for up to 7,000,000 warrants to purchase common stock to be issued in the future, assuming certain conditions are met, and the aggregate exercise price of such warrants.”

Signed by Lisa Walters-Hoffert, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 26, 2023. Read the notice at the SEC.

optionsSEC
Nov 2019$4 MPrivate placement after listing$2 to $10 million

Dare Bioscience, Inc.: Private sale, Nov 2019

Investors in this round

28 investors had bought by the notice of Sep 7, 2021: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Dare Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lisa Martucci Walters-Hoffert · Executive Officer
  • Sabrina Martucci Johnson · Executive Officer, Director
  • Cheryl J. Blanchard · Director
  • Gregory W. Matz · Director
  • Jessica D. Grossman · Director
  • Robin J. Steele · Director
  • Susan L. Kelley · Director
  • William H. Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes $1,175,000 of milestone payments paid in shares of common stock.”
  • On a merger: “Shares of Common Stock issued to the former stockholders of a company acquired by the issuer.”

Signed by Lisa Walters-Hoffert, Cfo. Source: SEC Form D and 1 amendment, newest notice filed Sep 7, 2021. Read the notice at the SEC.

equitySEC
Jul 2017$21 MPrivate placement after listing$10 to $50 million

Dare Bioscience, Inc.: Private sale, Jul 2017

Investors in this round

18 investors had bought by the notice of Jul 28, 2017: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Dare Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Lisa H. Walters-Hoffert · Executive Officer
  • Sabrina Martucci Johnson · Executive Officer, Director
  • Robin J. Steele · Director
  • Roger L. Hawley · Director
  • Susan L. Kelley · Director
  • William H. Rastetter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “Reference is made to that certain Proxy Statement filed by the Issuer with the Securities and Exchange Commission on June 19, 2017 (File No. 001-36395), as supplemented.”

Signed by Sabrina Martucci Johnson, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 28, 2017. Read the notice at the SEC.

equity, optionsSEC
Nov 2012$13 MNo. 6$10 to $50 million

Dare Bioscience, Inc.: Raise no. 6, Nov 2012

Investors in this round

16 investors had bought by the notice of Dec 14, 2012: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Dare Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $13 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexandra E. Glucksmann · Executive Officer
  • Christopher D.T. Guiffre · Executive Officer
  • Edward E. Garmey · Executive Officer
  • Jean E. Silveri · Executive Officer
  • Karen E. Roberts · Executive Officer
  • Oliver Fetzer · Executive Officer, Director
  • Alan Crane · Director
  • Bryan E. Roberts · Director
  • Ram E. Sasisekharan · Director
  • Robert E. Paull · Director
  • Robert E. Tepper · Director
  • Steven E. Hall · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jean Silveri, Senior Vice President, General Counsel and Secretary. Source: SEC Form D, newest notice filed Dec 14, 2012. Read the notice at the SEC.

equitySEC
Dec 2011$15 MNo. 5$10 to $50 million

Dare Bioscience, Inc.: Raise no. 5, Dec 2011

Investors in this round

19 investors had bought by the notice of Dec 15, 2011: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Dare Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexandra P. Glucksmann · Executive Officer
  • David P. DeMagistris · Executive Officer
  • Edward P. Garmey · Executive Officer
  • Jean P. Silveri · Executive Officer
  • Karen P. Roberts · Executive Officer
  • Oliver Fetzer · Executive Officer, Director
  • Alan Crane · Director
  • Bryan E. Roberts · Director
  • Ram E. Sasisekharan · Director
  • Robert E. Paull · Director
  • Robert E. Tepper · Director
  • Steven E. Hall · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jean Silveri, Senior Vice President, General Counsel and Secretary. Source: SEC Form D, newest notice filed Dec 15, 2011. Read the notice at the SEC.

equity, optionsSEC
Nov 2010$17 MNo. 4$10 to $50 million

Dare Bioscience, Inc.: Raise no. 4, Nov 2010

Investors in this round

17 investors had bought by the notice of Nov 19, 2010: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Dare Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $24 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexandra P. Glucksmann · Executive Officer
  • David P. DeMagistris · Executive Officer
  • Jean P. Silveri · Executive Officer
  • John P. Ryan · Executive Officer
  • Karen P. Roberts · Executive Officer
  • Oliver Fetzer · Executive Officer, Director
  • Alan Crane · Director
  • Bryan E. Roberts · Director
  • Ram E. Sasisekharan · Director
  • Robert E. Tepper · Director
  • Steven E. Hall · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jean Silveri, Senior Vice President, General Counsel and Secretary. Source: SEC Form D, newest notice filed Nov 19, 2010. Read the notice at the SEC.

equitySEC
Sep 2010$2 MNo. 3Under $2 million

Dare Bioscience, Inc.: Raise no. 3, Sep 2010

Investors in this round

15 investors had bought by the notice of Oct 13, 2010: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Dare Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexandra Glucksmann · Executive Officer
  • Jean E. Silveri · Executive Officer
  • Karen E. Roberts · Executive Officer
  • Oliver Fetzer · Executive Officer, Director
  • Alan E. Crane · Director
  • Bryan E. Roberts · Director
  • Ram E. Sasisekharan · Director
  • Robert E. Langer · Director
  • Robert E. Tepper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jean Silveri, Senior Vice President, General Counsel and Secretary. Source: SEC Form D, newest notice filed Oct 13, 2010. Read the notice at the SEC.

debt, optionsSEC
May 2010$5 MNo. 2$2 to $10 million

Dare Bioscience, Inc.: Raise no. 2, May 2010

Investors in this round

13 investors had bought by the notice of Jun 9, 2010: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Dare Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexandra Glucksmann · Executive Officer
  • Jean E. Silveri · Executive Officer
  • Karen E. Roberts · Executive Officer
  • Oliver Fetzer · Executive Officer, Director
  • Alan E. Crane · Director
  • Bryan E. Roberts · Director
  • Ram E. Sasisekharan · Director
  • Robert E. Langer · Director
  • Robert E. Tepper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jean Silveri, Senior Vice President, General Counsel and Secretary. Source: SEC Form D, newest notice filed Jun 9, 2010. Read the notice at the SEC.

debt, optionsSEC
Jul 2009$10 MNo. 1$10 to $50 million

Dare Bioscience, Inc.: Raise no. 1, Jul 2009

Investors in this round

13 investors had bought by the notice of Jul 27, 2009: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 24 investors are named for Dare Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexandra Glucksmann · Executive Officer
  • Oliver Fetzer · Executive Officer, Director
  • Alan Crane · Director
  • Bryan E. Roberts · Director
  • Ram Sasisekharan · Director
  • Robert Langer · Director
  • Robert Tepper · Director
  • Terry McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Oliver Fetzer, President. Source: SEC Form D, newest notice filed Jul 27, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Daré Bioscience, Inc., its revenue in fiscal 2025 came from these product and service lines: License fee revenue and other revenue $1.03 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Dare Bioscience, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2026).

    SEC Form D · Aug 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2026

Products and services#

No products or services of Dare Bioscience, Inc. are on record.

Investors#

24 named in official filings. Open an investor to see everything it has backed.

Investors in Dare Bioscience, Inc.
InvestorKindAmountRoundRoleSource
CVF LLCOthernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lilly Eli & CoOthernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lilly Ventures Fund I LLCVenture capitalnot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lux Capital Management, LLCFund or asset managernot statednot statedHeld Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lux Venture Associates II, LLCVenture capitalnot statednot statedHeld Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lux Venture Partners II, L.P.Venture capitalnot statednot statedHeld Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lux Ventures II, L.P.Venture capitalnot statednot statedHeld Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lux Ventures II Partners Fund I LLCVenture capitalnot statednot statedHeld Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Lux Ventures II Sidecar LPVenture capitalnot statednot statedHeld Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Management Co IV LLCVenture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Management Co. V, L.L.C.Venture capitalnot statednot statedHeld Series B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Entrepreneurs Fund IV LPVenture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Entrepreneurs' Fund V, L.P.Venture capitalnot statednot statedHeld Series B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners IV LPVenture capitalnot statednot statedHeld Series A, B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners Special Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Polaris Venture Partners V, L.P.Venture capitalnot statednot statedHeld Series B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
VEF Management V, LLCFund or asset managernot statednot statedHeld Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Venrock Associates V LPFund or asset managernot statednot statedHeld Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Venrock Entrepreneurs Fund V, L.P.Fund or asset managernot statednot statedHeld Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Venrock Management V, LLCFund or asset managernot statednot statedHeld Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Venrock Partners Management V, LLCFund or asset managernot statednot statedHeld Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Venrock Partners V L.P.Fund or asset managernot statednot statedHeld Series A, B, B-1, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
William H. RastetterPersonnot statednot statedHeld Series A, B, B-1, C and D preferred stock, director (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 19 investors.

Largest shareholders today

Institutions holding Daré Bioscience, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Dare Bioscience, Inc.
NameRoleNamed in
MarDee Martucci Haring-LaytonChief Accounting OfficerAug 2026
Sabrina Martucci JohnsonPresident and Chief Executive OfficerAug 2026
Lisa Martucci Walters-HoffertExecutive officerDec 2023
Lisa H. Walters-HoffertExecutive officerJul 2017
Alexandra E. GlucksmannExecutive officerDec 2012
Christopher D.T. GuiffreExecutive officerDec 2012
Edward E. GarmeyExecutive officerDec 2012
Jean E. SilveriExecutive officerDec 2012
Karen E. RobertsExecutive officerDec 2012
Oliver FetzerExecutive officerDec 2012
Alexandra P. GlucksmannExecutive officerDec 2011
David P. DeMagistrisExecutive officerDec 2011
Edward P. GarmeyExecutive officerDec 2011
Jean P. SilveriExecutive officerDec 2011
Karen P. RobertsExecutive officerDec 2011
John P. RyanExecutive officerNov 2010
Alexandra GlucksmannExecutive officerOct 2010
Gregory W. MatzDirectorAug 2026
Jessica D. GrossmanDirectorAug 2026
Robin J. SteeleDirectorAug 2026
Sabrina Martucci JohnsonPresident and Chief Executive OfficerAug 2026
Susan L. KelleyDirectorAug 2026
William H. RastetterDirectorAug 2026
Cheryl R. BlanchardDirectorDec 2023
Sophia N. Ononye-OnyiaDirectorDec 2023
Cheryl J. BlanchardDirectorSep 2021
Roger L. HawleyDirectorJul 2017
Alan CraneDirectorDec 2012
Bryan E. RobertsDirectorDec 2012
Oliver FetzerDirectorDec 2012
Ram E. SasisekharanDirectorDec 2012
Robert E. PaullDirectorDec 2012
Robert E. TepperDirectorDec 2012
Steven E. HallDirectorDec 2012
Alan E. CraneDirectorOct 2010
Robert E. LangerDirectorOct 2010
Ram SasisekharanDirectorJul 2009
Robert LangerDirectorJul 2009
Robert TepperDirectorJul 2009
Terry McGuireDirectorJul 2009

Went public since 2014. Its SEC number is that of a company listed on a stock exchange.